A new clinically based staging system for perihilar cholangiocarcinoma

American Journal of Gastroenterology

Volumn 109, Issue 12, 2014, Pages 1881-1890

  Chaiteerakij, Roongruedee ^a,b   Harmsen, William S ^a   Marrero, Carlos Romero ^a   Aboelsoud, Mohammed M ^a   Ndzengue, Albert ^a   Kaiya, Joseph ^a   Therneau, Terry M ^a   Sanchez, William ^a   Gores, Gregory J ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; DEMOGRAPHY; ELECTROCORTICOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; ICD-9-CM; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIHILAR CHOLANGIOCARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TUMOR BIOPSY; TUMOR VOLUME; BILE DUCT TUMOR; BLOOD; COHORT ANALYSIS; CYSTIC DUCT; HEPATIC DUCT; INTRAHEPATIC BILE DUCT; LYMPH NODE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; COHORT STUDIES; CYSTIC DUCT; FEMALE; HEPATIC DUCT, COMMON; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR BURDEN; YOUNG ADULT;

EID: 84925225780     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.327     Document Type: Article

References (37)

1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-44.
2. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013; 11: 13-21.
3. Gores GJ, Darwish Murad S, Heimbach JK et al. Liver transplantation for perihilar cholangiocarcinoma. Digest Dis 2013; 31: 126-9.
4. DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-62.
5. Nakeeb A, Tran KQ, Black MJ et al. Improved survival in resected biliary malignancies. Surgery 2002; 132: 555-63.
6. Darwish Murad S, Kim WR, Harnois DM et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98.
7. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81.
8. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstetr 1975; 140: 170-8.
9. Jarnagin WR, Fong Y, DeMatteo RP et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-17.
10. http://www.nccn.org/professionals/physician-gls/pdf/hepatobiliary.pdf. NCCN Guidelines Version 1, 2013.
11. Hiriart JB, Laurent C, Blanc JF. Perihilar cholangiocarcinoma, the need for a new staging system. Clin Res Hepatol Gastroenterol 2011; 35: 697-8.
12. Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009; 25: 238-9.
13. Heimbach JK, Gores GJ, Haddock MG et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82: 1703-7.
14. Fritcher EG, Kipp BR, Slezak JM et al. Correlating Routine Cytology, Quantitative Nuclear Morphology by Digital Image Analysis, and Genetic Alterations by Fluorescence In Situ Hybridization to Assess the Sensitivity of Cytology for Detecting Pancreatobiliary Tract Malignancy. Am J Clin Pathol 2007; 128: 272-9.
15. Fritcher EG, Kipp BR, Halling KC et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009; 136: 2180-6.
16. Kipp BR, Stadheim LM, Halling SA et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection ofmalignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-81.
17. Moreno Luna LE, Kipp B, Halling KC et al. Advanced cytologic techniques for the detection ofmalignant pancreatobiliary strictures. Gastroenterology 2006; 131: 1064-72.
18. Hassoun Z, Gores GJ, Rosen CB. Preliminary experience with liver transplantation in selected patients with unresectable hilar cholangiocarcinoma. Surg Oncol Clin N Am 2002; 11: 909-21.
19. Heimbach JK, Haddock MG, Alberts SR et al. Transplantation for hilar cholangiocarcinoma. Liver Transpl 2004; 10: S65-S68.
20. Nagino M, Ebata T, Yokoyama Y et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg 2013; 258: 129-40.
21. de Jong MC, Marques H, Clary BM et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 2012; 118: 4737-47.
22. Matsuo K, Rocha FG, Ito K et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 2012; 215: 343-55.
23. Zervos EE, Osborne D, Goldin SB et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005; 190: 810-5.
24. Cho MS, Kim SH, Park SW et al. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012; 16: 1672-9.
25. Juntermanns B, Sotiropoulos GC, Radunz S et al. Comparison of the sixth and the sevenTheditions of the UICC classification for perihilar cholangiocarcinoma. Ann Surg Oncol 2013; 20: 277-84.
26. Murakami Y, Uemura K, Sudo T et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg 2013; 17: 1429-39.
27. Deoliveira ML, Schulick RD, Nimura Y et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53: 1363-71.
28. Ruzzenente A, Iacono C, Conci S et al. A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC). Surgery 2014; 155: 633-9.
29. Han Y, Zhang W, Liu Y. Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma. World J Surg 2013; 37: 2419-27.
30. Watanabe A, Suzuki H, Yokobori T et al. Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis. Cancer Sci 2013; 104: 1427-32.
31. Fabris L, Cadamuro M, Moserle L et al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011; 54: 890-9.
32. Tian F, Li D, Chen J et al. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma. Eur J Cancer 2013; 49: 1771-80.
33. Itatsu K, Zen Y, Yamaguchi J et al. Expression ofmatrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts. Hum Pathol 2008; 39: 710-9.
34. Tolek A, Wongkham C, Proungvitaya S et al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med 2012; 237: 1142-9.
35. Patel SH, Kooby DA, Staley CA 3rd et al. The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy? HPB (Oxford) 2011; 13: 605-11.
36. Xu YF, Yang XQ, Lu XF et al. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun 2014; 446: 54-60.
37. Ebata T, Nagino M, Kamiya J et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg 2003; 238: 720-7.